Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safusidenib in IDH1 Mutated Low Grade Glioma
NCT05577416Phase 1Completed
- Sponsor
- Melbourne Health
- Start
- Oct 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of safusidenib in low-grade glioma (LGG), sponsored by Melbourne Health. Primary endpoints: Feasibility of Phase 0 study in patient population at 14 months, Pharmacokinetic analysis of tumour tissue at 4 weeks and 4 more. Started Oct 2022; status: completed.
02
Drugs
safusidenib
03
Conditions
low-grade glioma (LGG)
Beyond the preview
Go deeper on NCT05577416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05577416.